Back to Search
Start Over
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
- Source :
- Journal of Thoracic Oncology, 10(10), 1451-1457. International Association for the Study of Lung Cancer, Gautschi, O, Milia, J, Cabarrou, B, Bluthgen, M V, Besse, B, Smit, E F, Wolf, J, Peters, S, Fruh, M, Koeberle, D, Oulkhouir, Y, Schuler, M, Curioni-Fontecedro, A, Huret, B, Kerjouan, M, Michels, S, Pall, G, Rothschild, S, Schmid-Bindert, G, Scheffler, M, Veillon, R, Wannesson, L, Diebold, J, Zalcman, G, Filleron, T & Mazieres, J 2015, ' Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort ', Journal of Thoracic Oncology, vol. 10, no. 10, pp. 1451-1457 . https://doi.org/10.1097/JTO.0000000000000625
- Publisher :
- International Association for the Study of Lung Cancer. Published by Elsevier Inc.
-
Abstract
- Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, and sorafenib as BRAF inhibitors are currently tested in clinical trials, but access for patients is limited. The aim of this study was to document the clinical course of patients treated outside of clinical trials. Methods We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors. Data were anonymized and centrally assessed for age, gender, smoking, histology, stage, local molecular diagnostic results, systemic therapies, and survival. Best response was assessed locally by RECIST1.1. Results We documented 35 patients treated in 17 centers with vemurafenib, dabrafenib, or sorafenib. Median age was 63 years (range 42–85); gender was balanced; 14 (40%) were never smokers; all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had other mutations; one of them had a concomitant KRAS mutation. Thirty (86%) patients had chemotherapy in the first line. Overall survival with first-line therapy was 25.3 months for V600E and 11.8 months for non-V600E. Thirty-one patients received one BRAF inhibitor, and four received a second inhibitor. Overall response rate with BRAF therapy was 53%, and disease control rate was 85%. Median progression-free survival with BRAF therapy was 5.0 months, and overall survival was 10.8 months. Conclusions These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.
- Subjects :
- Sorafenib
Oncology
Adult
Male
Proto-Oncogene Proteins B-raf
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Medizin
610 Medicine & health
Targeted therapy
BRAF
Cohort Studies
Internal medicine
medicine
Humans
Molecular Targeted Therapy
Lung cancer
Vemurafenib
Protein Kinase Inhibitors
neoplasms
Aged
Retrospective Studies
Aged, 80 and over
business.industry
Dabrafenib
Retrospective cohort study
Middle Aged
medicine.disease
digestive system diseases
Surgery
Clinical trial
2740 Pulmonary and Respiratory Medicine
10032 Clinic for Oncology and Hematology
2730 Oncology
Female
business
V600E
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 15560864
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Journal of Thoracic Oncology
- Accession number :
- edsair.doi.dedup.....43234d25ec2540e38c0210a2aa7cd068
- Full Text :
- https://doi.org/10.1097/JTO.0000000000000625